I heard about it from a friend: Assessing interest in buprenorphine treatment

Substance Abuse

Volumn 35, Issue 1, 2014, Pages 74-79

  Fox, Aaron D ^a   Shah, Pooja A ^b   Sohler, Nancy L ^c   Lopez, Carolina M ^d   Starrels, Joanna L ^a   Cunningham, Chinazo O ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^d New York Harm Reduction Educators   (United States)

Author keywords

Buprenorphine; drug dependence; heroin; syringe exchange programs

Indexed keywords

BUPRENORPHINE; NARCOTIC ANTAGONIST;

ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NEEDLE SHARING; OPIOID-RELATED DISORDERS; PSYCHOLOGY;

BUPRENORPHINE; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NEEDLE SHARING; OPIOID-RELATED DISORDERS;

EID: 84897730940     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2013.804484     Document Type: Article

References (46)

1. Substance Abuse and Mental Health Service Administration. Results from the 2011 National Survey on Drug Use and Health: National Findings. NSDUH Series H-44. Rockville, MD: Substance Abuse and Mental Health Service Administration; 2012. HHS Publication No. (SMA) 12-4713.
2. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2000-2010. State Admissions to Substance Abuse Treatment Services. DASIS Series: S-63. Rockville, MD: ubstance Abuse and Mental Health Services Administration; 2012. HHS Publication No. SMA-12-4729.
3. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
4. Ling W, Jacobs P, Hillhouse M, et al. From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat. 2010;38(Suppl 1):S53-S60.
5. Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39:96-104.
6. Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1: 62-67.
7. Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584-589.
8. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
9. Madden A, Lea T, Bath N, Winstock AR. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. 2008;27:671-678.
10. Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs. 2010;42:339-346.
11. Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients' reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4:204-210.
12. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441-452.
13. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
14. Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend. 2008;92:267-276.
15. Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3:17.
16. Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012;123:72-78.
17. Kresina TF, Litwin AH, Marion I, Lubran R, Clark HW. United States Government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. J Drug Policy Anal. 2009;2.
18. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25:91-103.
19. Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22:171-176.
20. Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioiddependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012;31:278-287.
21. Heller DI, Paone D, Siegler A, Karpati A. The syringe gap: an assessment of sterile syringe need and acquisition among syringe exchange program participants in New York City. Harm Reduct J. 2009;6:1.
22. Des Jarlais DC, Braine N, Friedmann P. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS Behav. 2007;11(6 Suppl):78-84.
23. McLean K. Needle exchange and the geography of survival in the South Bronx. Int J Drug Policy. 2012;23:295-302.
24. Kidorf M, Disney E, King V, Kolodner K, Beilenson P, Brooner RK. Challenges in motivating treatment enrollment in community syringe exchange participants. J Urban Health. 2005;82:456-467.
25. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
26. Prochaska JO. A stage paradigm for integrating clinical and public health approaches to smoking cessation. Addict Behav. 1996;21:721-732.
27. Riley ED, Safaeian M, Strathdee SA, Brooner RK, Beilenson P, Vlahov D. Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse. 2002;37:1869-1886.
28. Monte AA, Mandell T, Wilford BB, Tennyson J, Boyer EW. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009;28:226-231.
29. Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011;5:175-180.
30. McCarty D, Fuller BE, Arfken C, et al. Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv. 2007;58:181-190.
31. Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat. 2006;30:363-373.
32. Knudsen HK, Ducharme LJ, Roman PM. The adoption ofmedications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007;87: 164-174.
33. Knudsen HK, Abraham AJ, Johnson JA, Roman PM. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2009;37:307-312.
34. Ducharme LJ, Roman PM. Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption. J Subst Abuse Treat. 2009;37:90-94.
35. Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus. 2006;27:39-45.
36. Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25:215-224.
37. Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22: 1325-1329.
38. Davey MA, Latkin CA, Hua W, Tobin KE, Strathdee S. Individual and social network factors that predict entry to drug treatment. Am J Addict. 2007;16:38-45.
39. Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. N Engl J Med. 2008;358:2249-2258.
40. Tracy K, Burton M, Miescher A, et al. Mentorship for alcohol problems (MAP): a peer to peer modular intervention for outpatients. Alcohol Alcohol. 2011;47:42-47.
41. Smith JE, Meyers RJ, Miller WR. The community reinforcement approach to the treatment of substance use disorders. Am J Addict. 2001;10(Suppl):51-59.
42. Miller WR, Meyers RJ, Hiller-Sturmhofel S. The community reinforcement approach. Alcohol Res Health. 1999;23:116-121.
43. Tracy K, Burton M, Nich C, Rounsaville B. Utilizing peer mentorship to engage high recidivism substance-abusing patients in treatment. Am J Drug Alcohol Abuse. 2011;37:525-531.
44. Wells K, Klap R, Koike A, Sherbourne C. Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. Am J Psychiatry. 2001;158:2027-2032.
45. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15: 618-627.
46. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6:662-672.